PharmaFocus Today – Page 40 – media

Will Novo Nordisk’s Wegovy follow up with the price reduction of over 50% for Eli Lilly’s Zepbound?

MU Biotech Circle Recently, Eli Lilly announced plans to directly sell single dose vials of its weight loss drug Zepbound (tirzepatide) to consumers. The new prices for 2.5mg and 5.0mg doses are $99.75/vial and $137.25/vial, respectively, with corresponding monthly costs of $399 and $549, respectively, with a price reduction of over 50%. Novo Nordisk may adopt a similar strategy towards its Wegovy, with specific details to be revealed by its CEO during a Senate Health Committee hearing on September 24th. Analysts have responded positively to Eli Lilly’s move to lower Zepbound prices and offer the drug through its new self funded pharmacy component on its direct to consumer platform LillyDirect (launched in January this year). Joon Lee, an analyst at Truist Securities, believes that given the high demand for patients willing to purchase at their own expense, there is no reason why other GLP-1 manufacturers should not adopt similar strategies. ...
- Source: drugdu
- 74
- September 4, 2024
Jimin Health aims at the new biomedical technology track

As one of the first hospitals to enter the Boao Lecheng International Medical Tourism Zone in Hainan, the Boao International Hospital of Jimin Health, relying on the policy advantage of “early and pilot implementation” of the zone, has focused its R&D efforts on two major R&D pipelines of adipose-derived mesenchymal stem cells and dendritic cells in the field of cellular therapeutic drugs. Tian Yunfei, director and president of Jimin Health, recently said in an interview with China Securities Journal, “Based on the long-term optimism for the development prospect of cell therapy drugs, Jimin Health will focus on the research and development of Boao International Hospital’s cell therapy drug pipeline in the future.” Joining hands with stem cell experts JiminHealth’s 2024 semi-annual report disclosed the appointment of Jonathan Robert Lakey as the chief scientist of the International Regenerative Medicine Research Center of Boao International Hospital, a controlling subsidiary, and that the ...
- Source: drugdu
- 64
- September 4, 2024
The “scale trap” of chain drug stores

1. The more you open, the more you lose In the past few years, drug stores have sprung up all over the country. Whether it is a first-tier city or a small county town, you can see a drug store almost every 50 meters, and there are at least three drug stores at the entrance of a community. The “proliferation” of drug stores has exceeded many people’s imagination. By the end of 2023, there will be nearly 700,000 retail pharmacies in my country, which is more than 100,000 more than the milk tea shops that are everywhere on the streets. In 2012, there were only 440,000 drug stores in my country. In 12 years, the number of drug stores has increased by nearly 50%. Although milk tea shops and snack shops have sprung up in the streets and alleys, they are nothing compared to the expansion speed of chain drug ...
- Source: drugdu
- 53
- September 4, 2024
Under the great changes! Thinking about the development strategy of pharmaceutical companies

1. Cycles exist objectively, but they are not impossible to cross In recent years, the concept we first used was the “new normal”. The term “new normal” actually lowers social expectations in advance. Later, many experts introduced the concept of “cycle” with the intention of incorporating the current economic situation into a historical cycle. Admittedly, economic development has cycles, and even the spread of viruses has cycles. However, “today’s economic and social conditions should mainly be the result of active choices made by decision-makers. Cyclical factors have an effect but are not decisive, or the adjustment of development direction “encounters” cyclical factors”-excerpted from Du Chen’s “Our Times and Us in the Times”. 2. The current difficulties may only be the initial stage The “new cycle” has just begun, and we must be prepared for long-term hard work. Combining data from the National Bureau of Statistics, Minnet, IQVIA, etc., the average ...
- Source: drugdu
- 51
- September 4, 2024
Yuheng Pharmaceuticals sees a turnaround

Yuheng Pharmaceutical, founded by Zhu Jiman, the “Northeast Medicine King”, once became famous in the industry through continuous large-scale mergers and acquisitions of many pharmaceutical companies such as Auno Pharmaceutical and Shanghai Huatuo. In the end, it fell into a downturn due to frequent mergers and acquisitions. Recently, Yuheng Pharmaceutical handed in its first semi-annual report after the reorganization. The net profit attributable to the parent company in the first half of 2024 was 125 million yuan, a year-on-year increase of 342.39%, and a substantial increase in profits. How did Yuheng Pharmaceutical recover so quickly? We have to talk about PD-1. There are many competitors in the PD-1/L1 field. In June 2024, the listing application of Enlangsubai monoclonal antibody of Shijiazhuang Pharmaceutical Group was officially approved. So far, there are at least 15 PD-1/L1 monoclonal antibodies approved for listing in China. The PD-1/L1 track, which is being chased by major ...
- Source: drugdu
- 63
- September 4, 2024
Down payment of 150 million! Non small cell lung cancer pipeline BD+1

On August 30, 2024, Shanghai Iris Pharmaceutical Technology Co., Ltd. (Iris) (688578. SH) signed a strategic cooperation agreement with Carcos Pharmaceutical (1167. HK). Iris obtained the exclusive license to research, develop, produce, register and commercialize the KRAS G12C inhibitor Golarese and SHP2 inhibitor JAB-3312 in China (including Chinese Mainland, Hong Kong, Macao and Taiwan). According to the terms of the agreement, Elys will pay 150 million yuan in head of state payments, up to 700 million yuan in development and sales milestone payments, and double-digit sales commissions to Gakos for this authorization, including value-added tax. Established in 2004, Elise is an innovative pharmaceutical company dedicated to providing unmet clinical needs for patients worldwide. It was listed on the Shanghai Stock Exchange’s Science and Technology Innovation Board in 2020. Since its establishment, the company has adhered to independent innovation and established a complete new drug research and development system, covering various ...
- Source: drugdu
- 128
- September 3, 2024
Originating from Tsinghua University, a brain computer interface company in China plans to IPO

On August 28th, the official website of the China Securities Regulatory Commission disclosed that Beijing Pinchi Medical Equipment Co., Ltd. (hereinafter referred to as “Pinchi Medical”) has completed the registration of coaching and filing with the Beijing Securities Regulatory Bureau, and plans to conduct an initial public offering and listing. The coaching securities firm is China International Capital Corporation (CICC). It is reported that Pinchi Medical is a leader in the field of neural regulation in China, specializing in the research and development, production, and sales of a series of neural regulation products such as brain pacemakers, vagus nerve stimulators, spinal cord stimulators, and sacral nerve stimulators. 1st developer in China to offer a full range of neural regulation products Since its establishment in 2008, Pinchi Medical has continued to deeply cultivate the field of neural regulation. With profound technological accumulation and innovative spirit, it has undertaken multiple national key ...
- Source: drugdu
- 116
- September 3, 2024
2024 Chinese Small Molecule Targeted Anti Tumor Drugs White Paper

The current development status of the global and Chinese small molecule anti-tumor targeted drug industry China is a major cancer country in the world. The main types of malignant cancer in China are lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer and esophageal cancer. The high incidence and death of cancer patients has created a huge demand for innovative therapeutic drugs and treatment schemes. From the perspective of the overall Chinese market, the market size of small molecule anti-tumor drugs in China will reach 73.4 billion yuan in 2023, and it is expected to further grow to 207.5 billion yuan in 2030. The compound annual growth rate during this period is 16.0%, far exceeding the global level during the same period, demonstrating the strong growth momentum of the Chinese market. Representative enterprise of China’s small molecule anti-tumor targeted drug industry – Zhejiang Tongtongkang Pharmaceutical From the perspective of ...
- Source: drugdu
- 96
- September 3, 2024
Warner Pharmaceutical’s Half Year Report Achieves New High in Total Assets, Highly Recommended by Securities Firms

Source: Securities Times · E Company Latest price: 38.25 Price fluctuation: -0.75 Price range: -1.92% Transaction volume: 4481 lots Transaction amount: 17.06 million Turnover rate: 0.48% Price to earnings ratio: 15.9 Total market value: 3.59 billion On August 31st, Warner Bros. Pharmaceutical (688799. SH) released its 2024 semi annual report, achieving a revenue of 739 million yuan in the first half of the year, a year-on-year increase of 2.34%; Realize a net profit attributable to the parent company of 113 million yuan, a year-on-year increase of 0.52%. The basic earnings per share are 1.20 yuan. Simultaneously disclosed is the 2023 annual profit distribution plan, in which the company plans to distribute a cash dividend of 9 yuan (including tax) for every 10 shares to all shareholders, totaling 84.42 million yuan (including tax). If this profit distribution plan is approved by the shareholders’ meeting, the company will distribute a total of ...
- Source: drugdu
- 69
- September 3, 2024
BeiGene’s “BTK Double Swords” Unleashed

When it comes to BeiGene’s BTK, you will think of zanubrutinib without thinking, but BeiGene’s BTK inhibitors are not limited to zanubrutinib. BGB-16673, which is under development in the pipeline, is another potential “sharp sword”. Recently, BeiGene’s BTK PROTAC molecule BGB-16673 was granted fast track qualification by the FDA for CLL/SLL patients who have undergone at least two lines of treatment, including BTK inhibitors and Bcl-2 inhibitors. Since the first BTK inhibitor ibrutinib was approved for marketing in 2013, 6 BTK inhibitors have been approved for marketing worldwide. Although many BTK inhibitors have been approved for marketing and these drugs have demonstrated excellent efficacy, they still have certain limitations, namely the problem of drug resistance. PROTAC (protein degradation) has been a very hot research and development track in recent years. Compared with small molecule inhibitors, PROTAC degraders have many advantages: they expand the druggable targets and can target target proteins ...
- Source: drugdu
- 83
- September 3, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.